Literature DB >> 2447690

Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506.

N Inamura1, K Nakahara, T Kino, T Goto, H Aoki, I Yamaguchi, M Kohsaka, T Ochiai.   

Abstract

FK506, an immunosuppresant, was isolated from Streptomyces tsukubaensis. Intramuscular administration of FK506 (0.32 mg/kg or more) 5 days a week for two weeks after grafting prolonged the acceptance time of F344 skin allograft to WKA rats. Similar results were obtained with cyclosporine at 32 mg/kg or more, but other immunosuppressives (i.e., prednisolone, azathioprine, and bredinin) gave only a marginal prolongation. The prolonging effect of FK506 was obtained in various donor-recipient combinations across a major or minor histocompatibility barrier. The agent also prolonged the acceptance time of mouse skin xenografts to rats. Furthermore, maintenance doses of 3.2 or 0.32 mg/kg twice a week after an initial 14-day treatment with the agent at 3.2 mg/kg gave graft survival as long as the treatment was continued for more than 120 days. Our findings show that FK506 has a potent immunosuppressive effect in rats and suggest that the agent merits further investigation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447690     DOI: 10.1097/00007890-198801000-00042

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

Review 1.  The biosynthetic pathway of FK506 and its engineering: from past achievements to future prospects.

Authors:  Yeon Hee Ban; Sung Ryeol Park; Yeo Joon Yoon
Journal:  J Ind Microbiol Biotechnol       Date:  2015-09-05       Impact factor: 3.346

2.  Pathologic observations in human allograft recipients treated with FK 506.

Authors:  A J Demetris; J J Fung; S Todo; B Banner; T Zerbe; G Sysyn; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506.

Authors:  G Eiras; O Imventarza; N Murase; Y Ueda; S Todo; T Starzl; R J Duquesnoy; A Zeevi
Journal:  Transplantation       Date:  1990-06       Impact factor: 4.939

4.  Neurologic complications of FK 506.

Authors:  B H Eidelman; K Abu-Elmagd; J Wilson; J J Fung; M Alessiani; A Jain; S Takaya; S N Todo; A Tzakis; D Van Thiel
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  Inhibition by FK506 of established lesions of collagen-induced arthritis in rats.

Authors:  C Arita; T Hotokebuchi; H Miyahara; K Arai; Y Sugioka; N Kaibara
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

6.  Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal.

Authors:  J Woo; C S Ross; J I Milton; A W Thomson
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

7.  Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506.

Authors:  K Yamamoto; A Mori; T Nakahama; M Ito; H Okudaira; T Miyamoto
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

8.  Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation.

Authors:  T Fujisawa; Y Saitoh; N Urabe; T Takeda; Y Sekine; M Baba; Y Yamaguchi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 9.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

10.  Reversal of multidrug resistance by an immunosuppressive agent FK-506.

Authors:  M Naito; T Oh-hara; A Yamazaki; T Danki; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.